Keep up-to-date with BMS Canada
Kirkland, QC – November 26, 2014
MONTREAL, QUEBEC, November 19, 2014
NEW PD-1 IMMUNE CHECKPOINT INHIBITOR OPDIVO (NIVOLUMAB) FIRST TO DEMONSTRATE SURVIVAL BENEFIT IN PHASE 3 TRIAL IN TREATMENT NAÏVE ADVANCED MELANOMAResults of study conducted in Canada, Australia and Europe presented at Society for Melanoma Research and published in The New England Journal of Medicine show one-year survival rate of 73% in patients on Opdivo, versus 42% on dacarbazine and a 58% decrease in the risk of death (Hazard Ratio [HR] = 0.42, p<0.0001).
Categories: Public Communication
MONTREAL, QUEBEC – November 13, 2014
BRISTOL-MYERS SQUIBB ANNOUNCES HIGH CURE RATES FOR GENOTYPE 3 HEPATITIS C USING COMBINATION OF DACLATASVIR AND SOFOSBUVIR IN ALLY-3 TRIAL• Sustained virologic response after 12 weeks achieved in 90% of treatment-naïve and 86% of treatment-experienced patients in first all-oral, ribavirin-free treatment regimen in difficult-to-treat genotype 3.
Categories: Hepatitis C
Expanded Access Programs
Expanded Access, Named Patient and Emergency Use Programs for Bristol-Myers Squibb Medicines. Find out more.
Events & Programs
BMS Canada is committed to community involvement. Find out more.
Looking for a Great Career?
Bristol-Myers Squibb Canada can offer you the challenge and support you are looking for in a friendly, motivating and exciting atmosphere. Find out more.